Form 4: ADMA Biologics COO Reports Stock Transaction Following RSU Vesting

ADMA Biologics' COO, Kaitlin M. Kestenberg-Messina, reported a transaction involving the withholding of 1,854 shares to cover taxes upon the vesting of restricted stock units.

Summary

• Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reported a transaction on December 31, 2024.
• The transaction involved the withholding of 1,854 common stock shares to cover tax obligations related to the vesting of restricted stock units (RSUs).
• This was not an open market sale of securities.
• Following the transaction, Kestenberg-Messina beneficially owns 444,587 shares of ADMA Biologics common stock.
• This total includes unvested RSUs granted on various dates and shares from prior net settlements of RSUs after tax withholdings.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing of an insider transaction, which is neither positive nor negative for the company's outlook.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the stock ownership of key executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, as mandated by the SEC.
• The reporting of RSU vesting and tax withholding is a common occurrence for executives receiving equity compensation.
• The level of detail provided in the filing is consistent with SEC requirements for transparency.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it is a routine tax withholding event.
• The transaction does not impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

ADMA Biologics, stock transaction, Form 4, restricted stock units, RSU, insider trading, Kaitlin M. Kestenberg-Messina, COO, tax withholding, beneficial ownership